WALSH MCDERMOTT; CARL MUSCHENHEIM, F.A.C.P.; SUSAN J. HADLEY; PAUL A. BUNN; ROSEMARY V. GORMAN
This content is PDF only. Please click on the PDF icon to access.
Shortly after the first report on streptomycin by Waksman and his associates,1 Feldman and Hinshaw observed that the drug exerted a pronounced effect upon the course of tuberculous infections in guinea pigs.2 On the basis of these findings, a clinical investigation was started, and in September 1945 Hinshaw and Feldman reported that streptomycin exerted a suppressive effect upon the course of various forms of tuberculous infections in humans.3 Although the therapeutic claims of these investigators were notably restrained in this and their subsequent reports,4, 5 it was apparent that the alterations in the course of tuberculous infections observed by
MCDERMOTT W, MUSCHENHEIM C, HADLEY SJ, et al. STREPTOMYCIN IN THE TREATMENT OF TUBERCULOSIS IN HUMANS: I. MENINGITIS AND GENERALIZED HEMATOGENOUS TUBERCULOSIS1. Ann Intern Med. 1947;27:769–822. doi: 10.7326/0003-4819-27-5-769
Download citation file:
Published: Ann Intern Med. 1947;27(5):769-822.
CNS Infections, Infectious Disease, Mycobacterial Infections, Neurology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use